AAAAAA
Results:
1-16
|
Results: 16
Authors:
Darbar, D
Fromm, MF
Dell'Orto, S
Roden, DM
Citation: D. Darbar et al., Sympathetic activation enhances QT prolongation by quinidine, J CARD ELEC, 12(1), 2001, pp. 9-14
Authors:
Hitzl, M
Drescher, S
van der Kuip, H
Schaffeler, E
Fischer, J
Schwab, M
Eichelbaum, M
Fromm, MF
Citation: M. Hitzl et al., The C3435T mutation in the human MDR1 gene is associated with altered efflux of the P-glycoprotein substrate rhodamine 123 from CD56(+) natural killer cells, PHARMACOGEN, 11(4), 2001, pp. 293-298
Authors:
Pauli-Magnus, C
Rekersbrink, S
Klotz, U
Fromm, MF
Citation: C. Pauli-magnus et al., Interaction of omeprazole, lansoprazole and pantoprazole with P-glycoprotein, N-S ARCH PH, 364(6), 2001, pp. 551-557
Authors:
Pauli-Magnus, C
Murdter, T
Godel, A
Mettang, T
Eichelbaum, M
Klotz, U
Fromm, MF
Citation: C. Pauli-magnus et al., P-glycoprotein-mediated transport of digitoxin, alpha-methyldigoxin and beta-acetyldigoxin, N-S ARCH PH, 363(3), 2001, pp. 337-343
Authors:
von Richter, O
Greiner, B
Fromm, MF
Fraser, R
Omari, T
Barclay, ML
Dent, J
Somogyi, AA
Eichelbaum, M
Citation: O. Von Richter et al., Determination of in vivo absorption, metabolism, and transport of drugs bythe human intestinal wall and liver with a novel perfusion technique, CLIN PHARM, 70(3), 2001, pp. 217-227
Authors:
Busse, D
Fromm, MF
Morike, K
Drescher, S
Kuhlkamp, V
Eichelbaum, M
Citation: D. Busse et al., Disposition and pharmacologic effects of R/S-verapamil in patients with chronic atrial fibrillation: An investigation comparing single and multiple dosing, CLIN PHARM, 69(5), 2001, pp. 324-332
Authors:
Fromm, MF
Citation: Mf. Fromm, P-glycoprotein: a defense mechanism limiting oral bioavailability and CNS accumulation of drugs, INT J CL PH, 38(2), 2000, pp. 69-74
Authors:
Pauli-Magnus, C
von Richter, O
Burk, O
Ziegler, A
Mettang, T
Eichelbaum, M
Fromm, MF
Citation: C. Pauli-magnus et al., Characterization of the major metabolites of verapamil as substrates and inhibitors of P-glycoprotein, J PHARM EXP, 293(2), 2000, pp. 376-382
Authors:
Fromm, MF
Kauffmann, HM
Fritz, P
Burk, O
Kroemer, HK
Warzok, RW
Eichelbaum, M
Siegmund, W
Schrenk, D
Citation: Mf. Fromm et al., The effect of rifampin treatment on intestinal expression of human MRP transporters, AM J PATH, 157(5), 2000, pp. 1575-1580
Authors:
Dilger, K
Greiner, B
Fromm, MF
Hofmann, U
Kroemer, HK
Eichelbaum, M
Citation: K. Dilger et al., Consequences of rifampicin treatment on propafenone disposition in extensive and poor metabolizers of CYP2D6, PHARMACOGEN, 9(5), 1999, pp. 551-559
Authors:
Kim, RB
Wandel, C
Leake, B
Cvetkovic, M
Fromm, MF
Dempsey, PJ
Roden, MM
Belas, F
Chaudhary, AK
Roden, DM
Wood, AJJ
Wilkinson, GR
Citation: Rb. Kim et al., Interrelationship between substrates and inhibitors of human CYP3A and P-glycoprotein, PHARM RES, 16(3), 1999, pp. 408-414
Authors:
Cvetkovic, M
Leake, B
Fromm, MF
Wilkinson, GR
Kim, RB
Citation: M. Cvetkovic et al., OATP and P-glycoprotein transporters mediate the cellular uptake and excretion of fexofenadine, DRUG META D, 27(8), 1999, pp. 866-871
Authors:
Fromm, MF
Darbar, D
Dell'Orto, S
Roden, DM
Citation: Mf. Fromm et al., Modulation of effect of dietary salt on prehepatic first-pass metabolism: Effects of beta-blockade and intravenous salt loading, J PHARM EXP, 290(1), 1999, pp. 253-258
Authors:
Fromm, MF
Kim, RB
Stein, CM
Wilkinson, GR
Roden, DM
Citation: Mf. Fromm et al., Inhibition of P-glycoprotein-mediated drug transport - A unifying mechanism to explain the interaction between digoxin and quinidine, CIRCULATION, 99(4), 1999, pp. 552-557
Authors:
Fromm, MF
Leake, B
Roden, DM
Wilkinson, GR
Kim, RB
Citation: Mf. Fromm et al., Human MRP3 transporter: identification of the 5 '-flanking region, genomicorganization and alternative splice variants, BBA-BIOMEMB, 1415(2), 1999, pp. 369-374
Authors:
Darbar, D
Fromm, MF
Dell'Orto, S
Kim, RB
Kroemer, HK
Eichelbaum, M
Roden, DM
Citation: D. Darbar et al., Modulation by dietary salt of verapamil disposition in humans, CIRCULATION, 98(24), 1998, pp. 2702-2708
Risultati:
1-16
|